Biogen (BIIB) Stock Forecast, Price Target & Predictions
BIIB Stock Forecast
Biogen stock forecast is as follows: an average price target of $276.38 (represents a 59.28% upside from BIIB’s last price of $173.52) and a rating consensus of 'Buy', based on 33 wall street analysts offering a 1-year stock forecast.
BIIB Price Target
The average price target for Biogen (BIIB) is $276.38 based on 1-year price targets from 33 Wall Street analysts in the past 3 months, with a price target range of $400.00 to $202.00. This represents a potential 59.28% upside from BIIB's last price of $173.52.
BIIB Analyst Ratings
According to 33 Wall Street analysts, Biogen's rating consensus is 'Buy'. The analyst rating breakdown for BIIB stock is 0 'Strong Buy' (0.00%), 24 'Buy' (72.73%), 9 'Hold' (27.27%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biogen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 31, 2024 | Jay Olson | Oppenheimer | $255.00 | $181.18 | 40.74% | 46.96% |
| Oct 31, 2024 | Terence Flynn | Morgan Stanley | $204.00 | $181.18 | 12.60% | 17.57% |
| Oct 30, 2024 | Christopher Raymond | Raymond James | $315.00 | $181.18 | 73.86% | 81.54% |
| Oct 30, 2024 | Salveen Richter | Goldman Sachs | $290.00 | $181.18 | 60.06% | 67.13% |
| Oct 17, 2024 | Evan Seigerman | BMO Capital | $230.00 | $188.16 | 22.23% | 32.55% |
| Oct 03, 2024 | Ashwani Verma | UBS | $202.00 | $188.74 | 7.03% | 16.41% |
| Sep 23, 2024 | Laura Chico | Wedbush | $205.00 | $199.36 | 2.83% | 18.14% |
| Jul 29, 2024 | Brian Skorney | Robert W. Baird | $294.00 | $212.70 | 38.22% | 69.43% |
| Jul 26, 2024 | Salveen Richter | Goldman Sachs | $342.00 | $211.17 | 61.95% | 97.10% |
| Jul 26, 2024 | Christopher Raymond | Piper Sandler | $307.00 | $211.17 | 45.38% | 76.92% |
The latest Biogen stock forecast, released on Oct 31, 2024 by Jay Olson from Oppenheimer, set a price target of $255.00, which represents a 40.74% increase from the stock price at the time of the forecast ($181.18), and a 46.96% increase from BIIB last price ($173.52).
Biogen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 7 | 23 |
| Avg Price Target | $258.80 | $243.00 | $275.78 |
| Last Closing Price | $173.52 | $173.52 | $173.52 |
| Upside/Downside | 49.15% | 40.04% | 58.93% |
In the current month, the average price target of Biogen stock is $258.80, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 49.15% increase as opposed to Biogen's last price of $173.52. This month's average price target is up 6.50% compared to last quarter, and down -6.16% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 31, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 31, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Oct 30, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 30, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Oct 17, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Oct 03, 2024 | UBS | Neutral | Neutral | Hold |
| Sep 24, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Sep 23, 2024 | Wells Fargo | Buy | Buy | Hold |
| Sep 23, 2024 | Wedbush | Underperform | Underperform | Hold |
| Sep 23, 2024 | Wedbush | Neutral | Neutral | Hold |
Biogen's last stock rating was published by Oppenheimer on Oct 31, 2024. The company gave BIIB a "Outperform" rating, the same as its previous rate.
Biogen Financial Forecast
Biogen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | $2.59B | $2.53B | $2.73B | $2.78B | $2.77B | $2.69B | $2.85B | $3.38B | $3.68B | $3.53B | $3.67B | $3.60B |
| Avg Forecast | $2.51B | $2.47B | $2.41B | $2.34B | $2.41B | $2.38B | $2.39B | $2.33B | $2.41B | $2.43B | $2.39B | $2.31B | $2.47B | $2.40B | $2.37B | $2.34B | $2.45B | $2.47B | $2.47B | $2.50B | $2.62B | $2.67B | $2.61B | $2.65B | $2.80B | $3.33B | $3.43B | $3.42B | $3.54B | $3.54B |
| High Forecast | $2.62B | $2.58B | $2.52B | $2.44B | $2.52B | $2.49B | $2.49B | $2.44B | $2.51B | $2.44B | $2.40B | $2.31B | $2.56B | $2.51B | $2.47B | $2.44B | $2.55B | $2.47B | $2.47B | $2.50B | $2.62B | $2.67B | $2.61B | $2.65B | $2.80B | $3.33B | $3.43B | $3.42B | $3.54B | $3.54B |
| Low Forecast | $2.38B | $2.34B | $2.29B | $2.22B | $2.29B | $2.26B | $2.27B | $2.25B | $2.23B | $2.43B | $2.39B | $2.31B | $2.35B | $2.29B | $2.24B | $2.22B | $2.32B | $2.47B | $2.47B | $2.50B | $2.62B | $2.67B | $2.61B | $2.65B | $2.80B | $3.33B | $3.43B | $3.42B | $3.54B | $3.54B |
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 24 | 12 | 25 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.04% | 1.05% | 1.04% | 1.02% | 1.05% | 1.01% | 1.04% | 1.04% | 1.06% | 1.02% | 1.02% | 1.01% | 1.07% | 1.03% | 1.04% | 1.02% |
Biogen's average Quarter revenue forecast for Dec 23 based on 27 analysts is $2.47B, with a low forecast of $2.35B, and a high forecast of $2.56B. BIIB's average Quarter revenue forecast represents a -2.54% decrease compared to the company's last Quarter revenue of $2.53B (Sep 23).
Biogen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 24 | 12 | 25 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $371.70M | $708.60M | $577.10M | $515.10M | $971.00M | $1.04B | $739.60M | $1.01B | $502.80M | $168.70M | $666.00M | $517.60M | $1.13B | $2.17B | $1.86B | $1.87B | $2.13B |
| Avg Forecast | $875.66M | $861.24M | $840.25M | $813.89M | $840.03M | $830.67M | $832.95M | $813.20M | $839.96M | $848.05M | $833.39M | $906.78M | $859.02M | $835.92M | $824.48M | $824.35M | $1.11B | $860.07M | $861.72M | $749.41M | $912.66M | $929.83M | $908.92M | $626.36M | $974.21M | $1.16B | $1.19B | $1.52B | $1.23B | $1.23B |
| High Forecast | $913.56M | $898.52M | $876.62M | $849.12M | $876.39M | $866.62M | $869.00M | $851.27M | $874.39M | $848.64M | $834.60M | $1.09B | $890.44M | $875.55M | $860.16M | $989.22M | $1.33B | $860.07M | $861.72M | $899.29M | $912.66M | $929.83M | $908.92M | $751.63M | $974.21M | $1.16B | $1.19B | $1.82B | $1.23B | $1.23B |
| Low Forecast | $830.21M | $816.54M | $796.64M | $771.65M | $796.44M | $787.56M | $789.72M | $782.06M | $778.00M | $847.46M | $832.18M | $725.43M | $817.11M | $796.46M | $781.69M | $659.48M | $888.28M | $860.07M | $861.72M | $599.53M | $912.66M | $929.83M | $908.92M | $501.09M | $974.21M | $1.16B | $1.19B | $1.21B | $1.23B | $1.23B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | 0.86% | 0.70% | 0.46% | 1.13% | 1.21% | 0.99% | 1.11% | 0.54% | 0.19% | 1.06% | 0.53% | 0.98% | 1.81% | 1.22% | 1.52% | 1.73% |
27 analysts predict BIIB's average Quarter EBITDA for Dec 23 to be $859.02M, with a high of $890.44M and a low of $817.11M. This is 131.10% upper than Biogen's previous annual EBITDA (Sep 23) of $371.70M.
Biogen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 24 | 12 | 25 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-68.10M | $591.60M | $387.90M | $550.40M | $1.13B | $1.06B | $221.80M | $-38.20M | $329.20M | $448.50M | $410.20M | $357.90M | $701.50M | $1.54B | $1.40B | $1.44B | $1.55B |
| Avg Forecast | $617.81M | $481.09M | $520.73M | $486.66M | $562.59M | $581.67M | $613.78M | $549.42M | $501.74M | $550.39M | $593.52M | $431.38M | $464.54M | $579.74M | $551.00M | $392.17M | $403.82M | $601.96M | $592.38M | $356.51M | $492.71M | $596.18M | $663.72M | $385.78M | $699.11M | $1.18B | $1.17B | $1.14B | $1.17B | $1.21B |
| High Forecast | $652.58M | $508.16M | $550.03M | $514.05M | $594.25M | $614.39M | $648.31M | $747.55M | $557.98M | $550.87M | $597.02M | $517.66M | $567.45M | $653.84M | $582.00M | $470.60M | $484.59M | $601.96M | $592.38M | $427.82M | $492.71M | $596.18M | $663.72M | $462.94M | $699.11M | $1.18B | $1.17B | $1.37B | $1.17B | $1.21B |
| Low Forecast | $576.13M | $448.63M | $485.60M | $453.83M | $524.63M | $542.42M | $572.37M | $304.92M | $386.29M | $549.91M | $590.02M | $345.11M | $404.27M | $451.88M | $513.82M | $313.73M | $323.06M | $601.96M | $592.38M | $285.21M | $492.71M | $596.18M | $663.72M | $308.63M | $699.11M | $1.18B | $1.17B | $915.12M | $1.17B | $1.21B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12% | 1.07% | 0.99% | 1.36% | 1.89% | 1.79% | 0.62% | -0.08% | 0.55% | 0.68% | 1.06% | 0.51% | 0.59% | 1.32% | 1.22% | 1.23% | 1.28% |
Biogen's average Quarter net income forecast for Sep 23 is $579.74M, with a range of $451.88M to $653.84M. BIIB's average Quarter net income forecast represents a -2.01% decrease compared to the company's last Quarter net income of $591.60M (Jun 23).
Biogen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 24 | 12 | 25 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $788.20M | $548.00M | $605.00M | $632.80M | $563.30M | $572.60M | $634.90M | $787.90M | $654.10M | $637.30M | $595.00M | $806.20M | $573.10M | $555.10M | $570.10M | $664.90M | $554.50M |
| Avg Forecast | $548.23M | $539.21M | $526.07M | $509.56M | $525.93M | $520.06M | $521.49M | $509.13M | $525.88M | $530.95M | $521.77M | $901.53M | $537.81M | $523.35M | $516.19M | $819.57M | $864.13M | $538.47M | $539.51M | $745.07M | $571.40M | $582.15M | $569.06M | $559.58M | $609.94M | $727.27M | $748.03M | $466.11M | $771.61M | $771.73M |
| High Forecast | $571.96M | $562.54M | $548.83M | $531.62M | $548.69M | $542.57M | $544.06M | $532.96M | $547.44M | $531.32M | $522.53M | $1.08B | $557.49M | $548.16M | $538.53M | $983.49M | $1.04B | $538.47M | $539.51M | $894.08M | $571.40M | $582.15M | $569.06M | $671.50M | $609.94M | $727.27M | $748.03M | $559.33M | $771.61M | $771.73M |
| Low Forecast | $519.78M | $511.22M | $498.76M | $483.12M | $498.63M | $493.07M | $494.43M | $489.63M | $487.09M | $530.58M | $521.01M | $721.22M | $511.58M | $498.64M | $489.40M | $655.66M | $691.30M | $538.47M | $539.51M | $596.05M | $571.40M | $582.15M | $569.06M | $447.67M | $609.94M | $727.27M | $748.03M | $372.89M | $771.61M | $771.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51% | 1.06% | 0.74% | 0.73% | 1.05% | 1.06% | 0.85% | 1.38% | 1.12% | 1.12% | 1.06% | 1.32% | 0.79% | 0.74% | 1.22% | 0.86% | 0.72% |
Biogen's average Quarter SG&A projection for Dec 23 is $537.81M, based on 27 Wall Street analysts, with a range of $511.58M to $557.49M. The forecast indicates a -31.77% fall compared to BIIB last annual SG&A of $788.20M (Sep 23).
Biogen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 4 | 5 | 4 | 4 | 3 | 4 | 8 | 24 | 12 | 25 | 22 | 27 | 26 | 13 | 15 | 14 | 12 | 12 | 24 | 25 | 13 | 23 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.47 | $4.09 | $2.69 | $3.82 | $7.86 | $7.25 | $1.51 | $-0.26 | $2.22 | $3.00 | $2.70 | $2.33 | $4.47 | $9.60 | $8.10 | $8.10 | $8.40 |
| Avg Forecast | $4.23 | $3.30 | $3.57 | $3.34 | $3.86 | $3.99 | $4.21 | $3.77 | $3.44 | $3.77 | $4.07 | $3.47 | $3.18 | $3.97 | $3.78 | $3.28 | $3.49 | $4.13 | $4.06 | $4.34 | $3.38 | $4.09 | $4.55 | $4.98 | $4.79 | $8.09 | $8.02 | $7.72 | $8.03 | $8.30 |
| High Forecast | $4.47 | $3.48 | $3.77 | $3.52 | $4.07 | $4.21 | $4.44 | $5.12 | $3.82 | $3.78 | $4.09 | $3.48 | $3.89 | $4.48 | $3.99 | $3.46 | $3.69 | $4.13 | $4.06 | $4.34 | $3.38 | $4.09 | $4.55 | $4.98 | $4.79 | $8.09 | $8.02 | $7.72 | $8.03 | $8.30 |
| Low Forecast | $3.95 | $3.07 | $3.33 | $3.11 | $3.60 | $3.72 | $3.92 | $2.09 | $2.65 | $3.77 | $4.04 | $3.46 | $2.77 | $3.10 | $3.52 | $3.06 | $3.25 | $4.13 | $4.06 | $4.34 | $3.38 | $4.09 | $4.55 | $4.98 | $4.79 | $8.09 | $8.02 | $7.72 | $8.03 | $8.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.12% | 1.08% | 0.82% | 1.09% | 1.91% | 1.79% | 0.35% | -0.08% | 0.54% | 0.66% | 0.54% | 0.49% | 0.55% | 1.20% | 1.05% | 1.01% | 1.01% |
According to 26 Wall Street analysts, Biogen's projected average Quarter EPS for Sep 23 is $3.97, with a low estimate of $3.10 and a high estimate of $4.48. This represents a -2.85% decrease compared to BIIB previous annual EPS of $4.09 (Jun 23).
Biogen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PFE | Pfizer | $27.76 | $44.76 | 61.24% | Hold |
| BIIB | Biogen | $173.52 | $276.38 | 59.28% | Buy |
| GSK | GSK | $36.97 | $58.00 | 56.88% | Hold |
| MRK | Merck | $101.87 | $129.47 | 27.09% | Buy |
| BMY | Bristol-Myers Squibb Company | $55.45 | $64.57 | 16.45% | Hold |
| JNJ | Johnson & Johnson | $158.24 | $179.13 | 13.20% | Buy |
| SNY | Sanofi | $52.95 | $57.36 | 8.33% | Buy |
| NVS | Novartis | $110.52 | $116.33 | 5.26% | Hold |
| AMGN | Amgen | $316.91 | $293.15 | -7.50% | Buy |
| GILD | Gilead Sciences | $89.84 | $81.32 | -9.48% | Buy |
| ABBV | AbbVie | $200.47 | $174.04 | -13.18% | Buy |
BIIB Forecast FAQ
Is Biogen a good buy?
Yes, according to 33 Wall Street analysts, Biogen (BIIB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 24 'Buy' recommendations, accounting for 72.73% of BIIB's total ratings.
What is BIIB's price target?
Biogen (BIIB) average price target is $276.38 with a range of $202 to $400, implying a 59.28% from its last price of $173.52. The data is based on 33 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Biogen stock go up soon?
According to Wall Street analysts' prediction for BIIB stock, the company can go up by 59.28% (from the last price of $173.52 to the average price target of $276.38), up by 130.52% based on the highest stock price target, and up by 16.41% based on the lowest stock price target.
Can Biogen stock reach $300?
BIIB's highest twelve months analyst stock price target of $400 supports the claim that Biogen can reach $300 in the near future.
What is Biogen's current price target trend?
5 Wall Street analysts forecast a $258.8 price target for Biogen (BIIB) this month, up 49.15% from its last price of $173.52. Compared to the last 3 and 12 months, the average price target increased by 40.04% and increased by 58.93%, respectively.
What are Biogen's analysts' financial forecasts?
Biogen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $9.52B (high $9.94B, low $9.06B), average EBITDA is $3.32B (high $3.46B, low $3.16B), average net income is $2.31B (high $2.6B, low $1.94B), average SG&A $2.08B (high $2.17B, low $1.98B), and average EPS is $15.82 (high $17.85, low $13.33). BIIB's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $9.73B (high $10.16B, low $9.23B), average EBITDA is $3.39B (high $3.54B, low $3.22B), average net income is $2.11B (high $2.22B, low $1.96B), average SG&A $2.12B (high $2.21B, low $2.01B), and average EPS is $14.44 (high $15.25, low $13.46).
Did the BIIB's actual financial results beat the analysts' financial forecasts?
Based on Biogen's last annual report (Dec 2022), the company's revenue was $10.17B, beating the average analysts forecast of $9.89B by 2.89%. Apple's EBITDA was $2.69B, missing the average prediction of $3.58B by -25.00%. The company's net income was $3.05B, beating the average estimation of $1.95B by 55.88%. Apple's SG&A was $2.4B, missing the average forecast of $2.69B by -10.55%. Lastly, the company's EPS was $20.96, beating the average prediction of $16.02 by 30.88%. In terms of the last quarterly report (Sep 2023), Biogen's revenue was $2.53B, beating the average analysts' forecast of $2.4B by 5.44%. The company's EBITDA was $371.7M, missing the average prediction of $835.92M by -55.53%. Biogen's net income was $-68.1M, missing the average estimation of $579.74M by -111.75%. The company's SG&A was $788.2M, beating the average forecast of $523.35M by 50.61%. Lastly, the company's EPS was $-0.47, missing the average prediction of $3.97 by -111.83%